$65.00
It is a remedy that stimulates the maturation of follicles. Contains LHG with LH (luteinizing hormone) activity, necessary for growth, maturation of gametes in women or men, as well as for the production of sex hormones.
Description
Pregnil Composition and release form
Active ingredient: chorionic chorionicgonadotropin (5000 IU / ml).
Available in powder form for solution preparation.
Pharmacological properties
It is a remedy that stimulates the maturation of follicles. Contains LHG with LH (luteinizing hormone) activity, necessary for growth, maturation of gametes in women or men, as well as for the production of sex hormones.
Indications
Pregnil is used in women:
- to prepare follicles for puncture with controlled ovarian stimulation (assisted reproduction);
- to stimulate ovulation with infertility caused by anovulation, impaired follicular maturation;
- to maintain the luteal phase with controlled stimulation of the ovaries (assisted reproduction) using analogs of gonadotropin-releasing hormone or other means of stimulating ovulation in infertility, provoked by anovulation in the absence of endogenous estrogen (group I ovarian insufficiency, WHO classification).
In men:
- with infertility associated with idiopathic dyspermia;
- with hypogonadotropic hypogonadism.
Boys:
- with delayed puberty associated with a lack of gonadotropin production by the pituitary gland;
- with cryptorchidism not associated with anatomical obstruction.
Contraindications
Pregnil is not used:
- with hypersensitivity to any component of the drug;
- in case of suspicion / detection of tumors of the mammary glands, ovaries, testicles, uterus, prostate, hypothalamus, pituitary gland;
- with primary hypofunction of the gonads;
- with congenital pathology of the genital organs, when pregnancy is contraindicated;
- with a fibroid tumor of the uterus, when pregnancy is contraindicated;
- with vaginal bleeding of an unexplained cause;
- with enlargement / ovarian cysts, not associated with polycystic syndrome.
Application during pregnancy and lactation
Given the purpose of the drug, it should not be used during pregnancy or breastfeeding.
The potential risk to the fetus and pregnancy is unknown.
There are no data on the release of hCG in breast milk.
Method of administration and dosage
Pregnil is intended for subcutaneous or intramuscular administration.
The powder should be dissolved immediately before use in the supplied solvent.
- For the induction of ovulation in infertility provoked by anovulation or impaired follicular maturation, as a rule, one injection is administered at a dose of 5000 to 10000 IU after FSH or HMG therapy.
- To prepare follicles for puncture, one injection is administered at a dose of 5,000 to 10,000 IU after FSH or HMG therapy.
- To support the luteal phase, 2-3 injections of 1000-3000 IU are shown (usually 9 days after ovulation or embryo transfer).
- For hypogonadotropic hypogonadism, idiopathic dispersion, 1000-2000 IU is shown 2-3 times / week. The course of treatment should last at least three months.
- With a delay in puberty – 1500 IU 2-3 times / week for at least six months.
Overdose
No cases described. There is a risk of developing ovarian hyperstimulation syndrome.
Side effects:
- General: fatigue, reactions at the injection site, headache.
- Digestive disorders: vomiting, abdominal pain.
- Mental disorders: irritability, depression, anxiety.
- Digestive Disorders: Diarrhea.
- Reproductive disorders: ovarian hyperstimulation syndrome, pain in the mammary glands.
- Immune disorders: allergic reactions.
Storage conditions and periods
Store Pregnil in intact packaging under the following temperature conditions: +2 to +8 degrees Celsius.
Store no more than three years from the date of manufacture.
The solution is intended for single use and immediate use after the first opening of the bottle and dilution.
It is allowed to introduce only a transparent solution that does not have foreign particles.
The remains of the unused solution must be destroyed.
Recent Reviews